Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1787 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Avapritinib Approved to Treat GIST with a Rare Gene Alteration February 6, 2020 Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... October 25, 2019 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective January 17, 2023 Load more HOT NEWS FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer Death Rates from Lung Cancer will Fall Overall in the EU... Phytochemicals and Antioxidants
